Assi R et al. Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: A single-center experience. Leuk Lymphoma 2021;62(4):909-17. Abstract
Atallah E et al. Assessment of outcomes after stopping tyrosine kinase inhibitors among patients with chronic myeloid leukemia: A nonrandomized clinical trial. JAMA Oncol 2021;7(1):42-50. Abstract
Brümmendorf TH et al. Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: Final results from the BFORE trial. Leukemia 2022;[Online ahead of print]. Abstract
Cortes J. Asciminib for the treatment of patients with chronic myeloid leukemia. Clin Adv Hematol Oncol 2021;19(4):207-8. Abstract
Cortes J et al. Bosutinib in newly diagnosed chronic myeloid leukemia: Gastrointestinal, liver, effusion and renal safety characterization in the BFORE trial. EHA 2022;Abstract P717.
Cortes J et al. Chronic myeloid leukaemia. Lancet 2021;398(10314):1914-26. Abstract
Cortes J et al. How to manage CML patients with comorbidities. Blood 2020;136(22):2507-12. Abstract
Cortes J, Lang F. Third-line therapy for chronic myeloid leukemia: Current status and future directions. J Hematol Oncol 2021;14(1):44. Abstract
Flynn KE et al. Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia. Haematologica 2022;[Online ahead of print]. Abstract
Hughes T et al. Trial in progress: A phase III study of asciminib vs an investigator-selected TKI in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP). EHA 2022;Abstract PB1904.
Januzzi JL et al. Correction: Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee. J Hematol Oncol 2022;15(1):33. Abstract
Lipton JH et al. Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option. Blood Rev 2022:[Online ahead of print]. Abstract
Pavlovsky C et al. Treatment-free remission in patients with chronic myeloid leukemia: Recommendations of the LALNET expert panel. Blood Adv 2021;5(23):4855-63. Abstract
Rea D et al. Efficacy and safety results from ASCEMBL, a phase 3 study of asciminib versus bosutinib (BOS) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after ≥2 prior tyrosine kinase inhibitors (TKIs): Week 96 update. ASCO 2022;Abstract 7004.
Schoenbeck KL et al. Patient-reported functional outcomes in patients with chronic myeloid leukemia after stopping tyrosine kinase inhibitors. J Natl Cancer Inst 2022;114(1):160-4. Abstract